Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

"Dusquetide for the treatment of oral mucositis in the pediatric population"

Award Number: R43DE028769
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2019
PERIOD OF PERFORMANCE END DATE: 08/14/2020

Group Awards By:

View Award Description

"Dusquetide for the treatment of oral mucositis in the pediatric population" - 7. Project Summary/Abstract This proposal requests funding to support the conduct of the juvenile toxicology study of SGX942 (dusquetide); the first step of embarking on a larger SGX942 pediatric development program. The major objectives of the study are to confirm the safety of SGX942 in a juvenile population and to facilitate a safety study in a pediatric patient population at high risk of developing severe oral mucositis (SOM). Mucositis is the clinical term for the painful inflammation and ulceration of the mucous membranes lining the digestive tract, usually as an adverse effect of chemotherapy/radiotherapy treatment for cancer. The mechanisms of mucositis have been linked to exaggerated response of the innate immune system to the tumor therapy induced tissue damage. Bacterial infection of the ulcerative lesions is now regarded as a secondary consequence of dysregulated local inflammation triggered by therapy-induced cell death, rather than as the primary cause of the lesions. The pathophysiology of OM is similar in adults and children with the main driver of OM intensity and duration being the chemotherapy and/or radiation treatment protocol. In the pediatric population, OM is a frequent (40-70%) significant side effect of chemotherapy and radiation treatment used in a variety of underlying diseases including allogeneic hematopoietic stem cell transplantation, solid tumors, and hematologic cancers, and for most tumor types there is no efficacious therapy available to treat the primary pathology. OM in pediatrics is often more frequent and more severe than in adults and has substantial impact on the quality of life, serious infection rates, and impacts the decisions about the duration and intensity of the chemoradiation therapy that, in turn, can impact survival. Preclinical studies with SGX942 revealed a significant reduction in both duration and peak intensity of oral mucositis caused by either fractionated radiation or chemotherapy. In animal studies, SGX942 does not interfere with recovery from leukopenia and is equally effective in leukopenic animals, while also providing anti-infective activity. IDRs have been shown to not interfere with responses of the adaptive immune system (generation of antibodies, Clinically, SGX942 has demonstrated statistically significant reduction of at least 50% duration of SOM in adult head and neck cancer patients undergoing chemoradiation therapy and is being evaluated in Phase 3 study in this same population. The innate immune system is highly conserved and generally established by 2 years of age; therefore SGX942 is expected to be equally efficacious in both adults and children. Testing in adolescent/young adult animals has demonstrated both anti- inflammatory and anti-infective activity. There is no currently approved therapy for OM in non-hematological malignancies and the only approved therapy in hematological malignancies is not considered efficacious in the context of allogeneic stem cell transplantation. The specific aim of the proposal is to confirm the safety of SGX942 compared to placebo in juvenile animals with maturing immune systems, including evaluation of the adaptive immune system (NK, T and B cells).


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $150,000 )
2019	2019	SOLIGENIX, INC.	29 EMMONS DR STE B10	PRINCETON	NJ	08540	MERCER	USA	Oral Diseases and Disorders Research	000	1	8/14/2019	NEW	$150,000
														Subtotal = $150,000

Grand Total All Awards = $150,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

"Dusquetide for the treatment of oral mucositis in the pediatric population"

Award Number: R43DE028769

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2019

PERIOD OF PERFORMANCE END DATE: 08/14/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer